Recent Analysts’ Ratings Changes for Evommune (EVMN)

A number of firms have modified their ratings and price targets on shares of Evommune (NYSE: EVMN) recently:

• 6/30/2026 – Evommune was downgraded by HC Wainwright from “buy” to “neutral”.
• 6/30/2026 – Evommune had its price target lowered by Morgan Stanley from $55.00 to $26.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – Evommune was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 6/29/2026 – Evommune was downgraded by Raymond James Financial, Inc. from “strong-buy” to “moderate buy”.
• 6/29/2026 – Evommune was downgraded by William Blair from “outperform” to “market perform”.
• 6/13/2026 – Evommune was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/26/2026 – Evommune had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 5/11/2026 – Evommune had its price target raised by Morgan Stanley from $54.00 to $55.00. They now have an “overweight” rating on the stock.
• 5/10/2026 – Evommune was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling

In other news, insider Jeegar Pravinkumar Patel sold 16,687 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $22.74, for a total transaction of $379,462.38. Following the transaction, the insider owned 46,403 shares of the company’s stock, valued at approximately $1,055,204.22. This represents a 26.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Janice Suzann Drew sold 20,000 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $22.63, for a total value of $452,600.00. Following the transaction, the insider directly owned 67,794 shares in the company, valued at $1,534,178.22. The trade was a 22.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 100,854 shares of company stock valued at $2,279,142 over the last 90 days.

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.